Post-EHA 2026 MPN Highlights

Featuring presentations & discussions on selected MPN abstracts from the 31st Congress of the European Hematology Association (EHA).  

Chair: Claire Harrison | Moderators: John Mascarenhas & Jean-Jacques Kiladjian

The Post-EHA 2026 MPN Highlights has been supported by BMS (Platinum Sponsor) and Karyopharm Therapeutics (Silver Sponsor). Supporters have no influence over the production of content.

Preliminary Agenda (subject to change)

Session 1: Novel treatment approaches for essential thrombocythemia & polycythemia vera  

Early versus delayed initiation of ropeginterferon alfa-2b in high-risk essential thrombocythaemia: Two-year results from the Phase 3 SURPASS-ET study (Abstract S219) | Speaker: Harinder Gill

Mutant calreticulin-specific monoclonal antibody, INCA033989, is well tolerated and achieves rapid and sustained hematologic and molecular responses in patients with essential thrombocythemia (ET) (Abstract PS1983) | Speaker: John Mascarenhas

Benefit of rusfertide maintained in patients (pts) with low-risk or high-risk polycythemia vera (PV): Efficacy and safety subgroup analysis from the randomized controlled Phase 3 VERIFY study (Abstract PF892) | Speaker: Valentin Garcia Gutierrez

Divesiran, a novel galnac conjugated siRNA, reduces phlebotomies, improves iron stores and symptoms in polycythemia vera patients in SANRECO Phase 1 study (Abstract PF886) | Speaker: Marina Kremyanskaya

Panel discussion 

Session 2: Latest in targeted therapies for myelofibrosis 

Results of AJX-101, a Phase 1 clinical trial of the type II JAK2 inhibitor AJ1-11095, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor (Abstract S218) | Speaker: John Mascarenhas

Mutant calreticulin–specific monoclonal antibody, INCA033989, is well tolerated and achieves robust spleen, anemia, and molecular responses in patients (pts) with myelofibrosis (MF) (Abstracts S216 & PF884) | Speaker: Claire Harrison

RALLY-MF: Initial efficacy of a Phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis (Abstract S306) | Speaker: Naseema Gangat

Efficacy and safety of luspatercept in patients with myelofibrosis on Janus kinase inhibitors who require red blood cell transfusions: Primary analysis of the Phase 3 INDEPENDENCE trial (Abstract S215) | Speaker: Francesco Passamonti

Selinexor plus ruxolitinib in Janus kinase inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial (Abstract LB5002) | Speaker: Claire Harrison

Panel discussion 

Session 3: Novel approaches for MPNs, MPN-associated disease and mastocytosis 

Development of a G6B directed antibody drug conjugate for the treatment of myeloproliferative neoplasms (Abstract S210) | Speaker: Adam Mead

Measurable residual disease in myelofibrosis: Clonal correlates from a prospective Phase II study (Abstract PF913) | Speaker: Nico Gagelmann

Antithrombotic and cytoreduction strategies in myeloproliferative neoplasm-associated splanchnic vein thrombosis: A retrospective study from the French intergroup of myeloproliferative neoplasms (Abstract PS1991) | Speaker: Alexandre Guy 

Efficacy and safety of bezuclastinib in patients with advanced systemic mastocytosis: primary results from the APEX study (Abstract S217) | Speaker: Daniel Deangelo

Panel discussion 

Conclusions and webinar close